70515-61-6

Basic information

• Product Name: 3-(DIMETHYLAMINO)-2-PHENYLACRYLONITRILE
• Synonyms: 3-(DIMETHYLAMINO)-2-PHENYLACRYLONITRILE;SALOR-INT L166871-1EA
• CAS NO: 70515-61-6
• Molecular Formula: C₁₁H₁₂N₂
• Molecular Weight: 172.23
• Mol File: 70515-61-6.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-(DIMETHYLAMINO)-2-PHENYLACRYLONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(DIMETHYLAMINO)-2-PHENYLACRYLONITRILE(70515-61-6)
• EPA Substance Registry System: 3-(DIMETHYLAMINO)-2-PHENYLACRYLONITRILE(70515-61-6)

Safety Data

• Hazardous Substances Data: 70515-61-6(Hazardous Substances Data)

Upstream product

• 5841-70-3 phenyl(formyl)acetonitrile 
• 68-12-2 N,N-dimethyl-formamide 
• 2214-82-6 Bis(dimethylamino)acetonitrile 
• 140-29-4 phenylacetonitrile 
• 1188-33-6 N,N-dimethylformamide diethyl diacetal 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 5815-08-7 tert-Butoxybis(dimethylamino)methane 
• 127-19-5 N,N-dimethyl acetamide 

Downstream Products

• 57999-06-1 4-phenyl-1H-pyrazol-5-amine 
• 1359943-36-4 6-phenylpyrazolo[1,5-a]pyrimidin-7-amine 
• 5591-70-8 4-phenyl-1H-pyrazol-3-ylamine 
• 320416-33-9 6-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 

Relevant articles and documents

HETEROCYCLE SUBSTITUTED AMINO-PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF

The present disclosure relates to heterocycle substituted amino-pyridine compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.

Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors

A structure-activity relationship study of dorsomorphin, a previously identified inhibitor of SMAD 1/5/8 phosphorylation by bone morphogenetic protein (BMP) type 1 receptors ALK2, 3, and 6, revealed that increased inhibitory activity could be accomplished by replacing the pendent 4-pyridine ring with 4-quinoline. The activity contributions of various nitrogen atoms in the core pyrazolo[1,5-a]pyrimidine ring were also examined by preparing and evaluating pyrrolo[1,2-a]pyrimidine and pyrazolo[1,5-a]pyridine derivatives. In addition, increased mouse liver microsome stability was achieved by replacing the ether substituent on the pendent phenyl ring with piperazine. Finally, an optimized compound 13 (LDN-193189 or DM-3189) demonstrated moderate pharmacokinetic characteristics (e.g., plasma t1/2 = 1.6 h) following intraperitoneal administration in mice. These studies provide useful molecular probes for examining the in vivo pharmacology of BMP signaling inhibition.

Orthoamides, XXXIII.-Contributions to the Chemistry of Bis(dialkylamino)acetonitriles

Bis(dialkylamino)acetonitriles 2a-d react with acetyl chloride and antimony pentachloride to give N,N,N',N'-tetraalkylformamidinium hexachloroantimonates 5a-d.Reaction of p-nitrophenol with 2a,b affords N,N,N',N'-tetraalkylformamidinium salts 8a,b, while reaction of aromatic aldehydes 11 with compounds 2 gives aryl(dialkylamino)acetonitriles 12.Phenyl isothiocyanate reacts with the nitriles 2a-c to give 1:1 adducts for which the structure of N,N,N',N'-tetraalkylformamidinium cyano-N-(phenyl)thioformamidates 19 is proposed.N,N,N',N'-Tetraalkylformamidinium p-toluenesulfonates 30a,b have been prepared from nitriles 2a,b and methyl p-toluoenesulfonate (28).Alkylation of 2c with 28 at higher temperatures affords 1,1-dimethylpiperidinium p-toluoenesulfonate (34) and a small amount (1-piperidinyl)malonodinitrile (33).The nitrile 2a reacts with CH acidic compounds such as ethyl cyanoacetate, malonodinitrile and benzyl cyanide to form the enamines 38.